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Factors Associated With Revision Surgery After Internal
Fixation of Hip Fractures
Sheila Sprague, PhD,*† Emil H. Schemitsch, MD, FRCSC,‡ Marc Swiontkowski, MD,§
Gregory J. Della Rocca, MD, PhD, FACS,║ Kyle J. Jeray, MD,¶ Susan Liew, MBBS,**
Gerard P. Slobogean, MD, MPH,†† Soﬁa Bzovsky, BSc,† Diane Heels-Ansdell, MSc,*
Qi Zhou, PhD,* and Mohit Bhandari, MD, PhD, FRCSC*† on behalf of the FAITH Investigators
Background: Femoral neck fractures are associated with high rates
of revision surgery after management with internal ﬁxation. Using data
from the Fixation using Alternative Implants for the Treatment of Hip
fractures (FAITH) trial evaluating methods of internal ﬁxation in
patients with femoral neck fractures, we investigated associations
between baseline and surgical factors and the need for revision surgery
to promote healing, relieve pain, treat infection or improve function
over 24 months postsurgery. Additionally, we investigated factors
associated with (1) hardware removal and (2) implant exchange from
cancellous screws (CS) or sliding hip screw (SHS) to total hip
arthroplasty, hemiarthroplasty, or another internal ﬁxation device.
Methods: We identiﬁed 15 potential factors a priori that may be
associated with revision surgery, 7 with hardware removal, and 14
with implant exchange. We used multivariable Cox proportional
hazards analyses in our investigation.
Results: Factors associated with increased risk of revision surgery
included: female sex, [hazard ratio (HR) 1.79, 95% conﬁdence interval
(CI) 1.25–2.50; P = 0.001], higher body mass index (for every 5-point
increase) (HR 1.19, 95% CI 1.02–1.39; P = 0.027), displaced fracture
(HR 2.16, 95% CI 1.44–3.23; P , 0.001), unacceptable quality of
implant placement (HR 2.70, 95% CI 1.59–4.55; P , 0.001), and
smokers treated with cancellous screws versus smokers treated with
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a sliding hip screw (HR 2.94, 95% CI 1.35–6.25; P = 0.006). Addi-
tionally, for every 10-year decrease in age, participants experienced an
average increased risk of 39% for hardware removal.
Conclusions: Results of this study may inform future research by
identifying high-risk patients who may be better treated with
arthroplasty and may beneﬁt from adjuncts to care (HR 1.39, 95%
CI 1.05–1.85; P = 0.020).
Key Words: femoral neck fracture, internal ﬁxation, cancellous
screws, sliding hip screw, revision surgery
Level of Evidence: Prognostic Level II. See Instructions for
Authors for a complete description of levels of evidence.
(J Orthop Trauma 2018;32:223–230)
INTRODUCTION
Hip fractures in elderly adults are common, affecting
approximately 1.6 million individuals worldwide each year and
resulting in a signiﬁcant amount of morbidity and mortality.1,2
Fractures of the femoral neck generally necessitate surgical
management with either internal ﬁxation or arthroplasty and
there exists controversy surrounding which of these 2 treatment
options is optimal in elderly patients.3 Typically, most displaced
fractures of the femoral neck are treated with arthroplasty, but
there exists evidence to suggest that internal ﬁxation is better
suited for treating undisplaced fractures.4 In addition, internal
ﬁxation does offer some advantages over arthroplasty, including
less surgical trauma, allowing the patient to retain their own
femoral head, and a marginal reduction in mortality and mor-
bidity in very frail patients.5 Regardless of treatment option,
fractures of the femoral neck are associated with high rates of
complications, including nonunion, delayed union, shortening,
infection, and avascular necrosis.3 Our recently completed Fix-
ation using Alternative Implants for the Treatment of Hip frac-
tures (FAITH) trial found a high revision surgery rate of 20.8%,
which was actually lower than a previously conducted meta-
analysis.6 Revision surgery prolongs patients’ recovery time, is
associated with higher rates of complications, and reduces pa-
tients’ health-related quality of life. Identifying factors that are
associated with revision surgery, and precisely which type of
revision surgery, can aid surgeons in making treatment deci-
sions and optimizing the care of hip fracture patients.
The recently completed FAITH randomized controlled
trial evaluated the effectiveness of internal ﬁxation with
a sliding hip screw (SHS) versus cancellous screws (CS) in
patients with a femoral neck fracture.7 The primary outcome
of this trial was the rate of revision surgery to promote frac-
ture healing, relieve pain, treat infection, or improve function
within 24 months of fracture.7 Our primary aim was to iden-
tify factors associated with an increased risk of revision sur-
gery, as deﬁned above, for patients enrolled in the FAITH
trial. Our secondary aims were to determine factors associated
with an increased risk of surgery for hardware removal,
deﬁned as the removal of CS or SHS, and surgery for implant
exchange, deﬁned as the conversion of CS or SHS to total hip
arthroplasty (THA), hemiarthroplasty (HA), or another inter-
nal ﬁxation device.
MATERIALS AND METHODS
FAITH Study Overview
The FAITH trial (Clinical Trials Identiﬁcation Number:
NCT00761813) enrolled 1079 patients with a low-energy
femoral neck fracture requiring fracture ﬁxation from 81 clinical
sites in the United States, Canada, Australia, the Netherlands,
Norway, Germany, the United Kingdom, and India. Patients
were assessed clinically at 1 and 10 weeks and 6, 9, 12, 18, and
24-months postsurgery. The primary outcome of the FAITH
trial was revision surgery to promote healing, relieve pain, treat
infection, or improve function over 24-months postsurgery.7,8
All revision surgeries were reviewed by a Central Adjudication
Committee. The trial protocol and results have been previously
published.7,8 The trial was approved by the Hamilton Integrated
Research Ethics Board (#06-402) and by all participating clinical
sites’ Research Ethics Boards/Institutional Review Boards.
Selection of Factors
Based on biologic rationale and previous literature,9
a priori we identiﬁed 22 potential factors that may be associ-
ated with revision surgery, from the baseline data, fracture
characteristics, and surgical data collected as part of the
FAITH trial (Table 1).7 When selecting factors for each anal-
ysis, we ensured that there were at least 10 events for each
factor to avoid having an overﬁtted or unstable model.10 Of
note, we had intended to include quality of reduction within
the models; however, less than 10 patients had unacceptable
quality of reduction. Therefore, this factor was not included in
the models. The number of factors included was based on the
primary outcome of the FAITH trial, revision surgery. As 224
participants had a revision surgery to promote healing, relieve
pain, treat infection or improve function over 24-months post-
surgery, all 22 preidentiﬁed factors (including levels) could
be used in our analysis. We included 15 factors with 22 levels
(Table 1) in our analysis. Because logistic and Cox models
require at least 10 events per covariate to produce stable
estimates,10 the minimum number participants required to
support the analysis of 22 factors would be 220 participants.
As 74 participants underwent hardware removal surgery, we
selected 7 factors that might be associated with hardware
removal in our model (Table 2). Finally, 150 participants
had implant exchange surgery. Therefore, we selected 14
factors to be included in this model (Table 3). For every factor
in each of our 3 models, we proposed a priori a hypothesized
effect and rationale for revision surgery, hardware removal,
and implant exchange, respectively.
Data Analysis
We used multivariable Cox proportional hazards regres-
sion stratiﬁed by center analyses to investigate the association
between our selected factors and increased risk of revision
surgery, hardware removal, and implant exchange. An inter-
action term between the randomized treatment and smoking
status was added to all models because this interaction was
found to be signiﬁcant in the FAITH primary paper.7 All
FAITH patients with complete data for all selected factors were
included in the analysis. Results were reported as adjusted
hazard ratios (HR), 95% conﬁdence intervals (CIs), and
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associated P-values. All tests were 2-tailed with alpha = 0.05.
We tested the assumption of proportional hazards for all inde-
pendent variables. We performed all analyses using SAS soft-
ware (version 9.4: SAS Institute, Cary, NC).
RESULTS
Participant Characteristics
Eight hundred ﬁfteen patients enrolled in the FAITH
trial had complete prognostic and follow-up data for the 15
selected factors and were included in the revision surgery
model (mean age: 73.4 years; 64% female). Complete data
were available for 894 (mean age: 73.4 years; 64% female)
and 823 (mean age: 73.6 years; 64% female) patients to
perform the analyses investigating factors associated with
hardware removal and implant exchange, respectively. Of the
patients included in this analysis, 191 patients had revision
surgeries to promote fracture healing, relieve pain, treat
infection, or improve function. Within this subset, there were
70 hardware removal surgeries and 143 implant exchange
surgeries (92 conversions to THA, 44 conversions to HA, and
9 IF exchanges).
Factors Associated With Revision Surgery
Female sex (HR 1.79, 95% CI 1.25–2.50; P = 0.001),
displaced fracture (HR 2.16, 95% CI 1.44–3.23; P , 0.001),
and a fracture conﬁguration corresponding to a Pauwels type III
as compared to type II (HR 2.13, 95% CI 1.28–3.57; P = 0.004)
were associated with a higher risk of revision surgery (Table 1).
Unacceptable quality of implant placement, which was adjudi-
cated by the Central Adjudication Committee and was deﬁned
in the FAITH trial as evidence of prominent screws (at the
lateral femoral cortex), screw penetration, and lag screw being
too high on immediate post-operative radiographs, was also
found to be associated with a higher risk of revision surgery
(HR 2.70, 95% CI 1.59–4.55; P, 0.001). Lastly, we found that
for every 5-point increase in body mass index (BMI), partic-
ipants experienced an average increased risk of 19% for revi-
sion surgery (HR 1.19, 95% CI 1.02–1.39; P = 0.027) during
the 24-month follow-up period. Additionally, we found that
being treated with CS (compared to SHS) increased the risk
TABLE 1. Factors Associated With Revision Surgery (n = 815;
191 Events)
Independent Variable
Hazard Ratio
(95% conﬁdence
interval) P
Gender
Female versus Male 1.79 (1.25–2.50) 0.001
Body mass index (Change in 5 points) 1.19 (1.02–1.39) 0.027
Fracture displacement
Displaced versus undisplaced 2.16 (1.44–3.23) 0.0002
Pauwels classiﬁcation
Type I versus type III 0.54 (0.26–1.15) 0.11
Type III versus type II 2.13 (1.28–3.57) 0.004
Quality of implant placement
Unacceptable versus acceptable; (Acceptable,
n = 776; Unacceptable, n = 39)
2.70 (1.59–4.55) 0.0002
Interaction 0.01
Smoking status
Current versus other (nonsmokers/
previous smokers) for Cancellous screws
1.89 (1.10–3.25) 0.021
Current versus other for sliding hip screw 0.62 (0.32–1.21) 0.16
Treatment
Cancellous screws versus sliding hip
screw for current smokers
2.94 (1.35–6.25) 0.006
Sliding hip screw versus cancellous screws
for other (nonsmokers/previous smokers)
1.05 (0.75–1.47) 0.77
Age (Change in 10 y) 1.05 (0.87–1.26) 0.62
ASA Classiﬁcation
Class II versus class I 0.76 (0.48–1.2) 0.24
Class III versus class I 0.84 (0.45–1.55) 0.57
Class IV versus class I 0.22 (0.04–1.1) 0.06
Class V versus class I No data
Pre-fracture living setting
Institutionalized versus Not institutionalized 0.97 (0.33–2.79) 0.95
Prefracture functional status
Using ambulatory aid versus independent
ambulator
1.47 (0.92–2.37) 0.11
Diabetes
Yes versus No 0.87 (0.54–1.38) 0.55
Level of the fracture line
Midcervical versus subcapital 0.73 (0.47–1.14) 0.16
Basal versus subcapital 0.55 (0.23–1.30) 0.17
Type of reduction
None versus open 0.82 (0.32–2.07) 0.67
Closed versus open 1.10 (0.43–2.79) 0.85
Time from injury to surgery (d) 1 (0.95–1.06) 0.88
TABLE 2. Factors Associated With Hardware Removal (n =
894; 70 Events)
Variable
Hazard Ratio
(95% conﬁdence
interval) P
Age (Change in 10 y) 1.39 (1.05–1.85) 0.020
Fracture displacement
Displaced versus undisplaced 2.91 (1.63–5.18) 0.0003
Quality of implant placement
Unacceptable versus acceptable 2.56 (1.11–5.88) 0.027
Interaction 0.02
Smoking status
Current versus other (nonsmokers/
previous smokers) for cancellous
screws
2.03 (0.91–4.51) 0.12
Current versus other for sliding hip
screw
0.35 (0.10–1.30) 0.08
Treatment
Sliding hip screw versus cancellous
screws for current smokers
0.09 (0.02–0.37) 0.001
Sliding hip screw versus cancellous
screws for other (nonsmokers/
previous smokers)
0.53 (0.29–0.96) 0.04
Body mass index (Change in 5 points) 1.03 (0.75–1.41) 0.86
Prefracture functional status
Using ambulatory aid versus independent
ambulator
0.62 (0.21–1.83) 0.39
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of revision surgery in patients who were smokers (HR 2.94,
95% CI 1.35–6.25; P = 0.006). No other factors were signiﬁ-
cantly associated with revision surgery (P . 0.05).
Factors Associated With Hardware Removal
Having a displaced fracture (HR 2.91, 95% CI
1.63–5.18; P , 0.001) and unacceptable quality of implant
placement (HR 2.56, 95% CI 1.11–5.88; P = 0.027) were
associated with an increased risk of hardware removal
(Table 2). We found that for every 10-year decrease in age,
participants experienced an average increased risk of 39% for
hardware removal (HR 1.39, 95% CI 1.05–1.85; P = 0.020)
during the 24-month follow-up period. Additionally, we
found that being treated with CS compared to a SHS was
associated with an increased risk of hardware removal; how-
ever, the treatment effect was signiﬁcantly higher in non-
smokers/prior smokers (HR 0.53, 95% CI 0.29–0.96; P =
0.040) compared to current smokers (HR 0.09, 95% CI
0.02–0.37; P = 0.001). BMI and prefracture functional status
were not associated with hardware removal (P . 0.05).
Factors Associated With Implant Exchange
Factors associated with an increased risk of implant
exchange included: female sex (HR 2.00, 95% CI 1.32–3.03;
P = 0.001), displaced fracture (HR 2.31, 95% CI 1.45–3.69; P
, 0.001), and unacceptable quality of implant placement (HR
2.38, 95% CI 1.32–4.35; P , 0.001) (Table 3). No other
factors were signiﬁcantly associated with implant exchange
(P . 0.05).
DISCUSSION
Using data from the FAITH trial, we investigated
factors associated with revision surgery, hardware removal,
and implant exchange in patients over the age of 50 with
a low-energy femoral neck fracture.7 To date, there have been
a limited number of studies that have enrolled large numbers
of femoral neck fracture patients treated with internal ﬁxation
across multiple centers and countries. Assessing nearly 1000
participants provided us with greater precision in our second-
ary analyses for determining the factors associated with over-
all revision surgery, hardware removal, and implant exchange
surgery.
In the FAITH primary paper, the interaction between
randomized treatment and smoking status was found to be
statistically signiﬁcant. When this interaction term was added
to the overall revision surgery model and the hardware
removal model, a SHS was found to be beneﬁcial in smokers
(compared to CS). The existing literature concerning the risk
of revision surgery in smokers following internal ﬁxation of
a femoral neck fracture is currently lacking. At this time, only
one other published study has evaluated factors associated
with revision surgery for femoral neck fractures, but this
study did not assess whether smoking was a factor.9 How-
ever, there is fracture healing literature that suggests that
smoking can have a negative effect on bone healing.11–14
One systematic review containing 9 tibia studies and 8 other
orthopaedic studies found that, overall, smoking had a nega-
tive effect on bone healing, in terms of delayed union, non-
union, and other complications.11 Another systematic review
found similar ﬁndings that smoking signiﬁcantly increased
the risk of nonunion of fractures overall [odds ratio (OR)
2.32; 95% CI 1.76–3.06; P , 0.001], tibial fractures (OR
2.16; 95% CI 1.55–3.01; P , 0.001), and open fractures
(OR 1.95; 95% CI 1.3–2.9; P , 0.001).12 Additionally,
a recently published prospective, multicentre, cohort study
evaluating the treatment of acute tibial plateau fractures with
open reduction and internal ﬁxation found that current smok-
ing was an independent risk factor for the development of
surgical site infection (OR 5.68; 95% CI 1.56–20.66; P =
0.009).13 Smoking is also known to have a negative impact
on bone density that impacts post-surgical fracture mechani-
cal stability.15 Our ﬁnding that smokers receiving a SHS will
have better outcomes needs to be conﬁrmed through future
research conducted on this topic.
Patients with a type III Pauwels fracture compared to
type II were found to be at a signiﬁcantly higher risk of
revision surgery in the current study. However, those with
a type III Pauwels fracture were not found to be at a higher
risk of revision surgery compared to patients with a type I
TABLE 3. Factors Associated With Implant Exchange (n = 823;
143 Events)
Variable
Hazard Ratio
(95% conﬁdence
interval) P
Gender
Female versus male 2.00 (1.32–3.03) 0.001
Fracture displacement
Displaced versus undisplaced 2.31 (1.45–3.69) 0.0005
Quality of implant placement: unacceptable
versus acceptable. (acceptable, n = 852;
unacceptable, n = 42)
2.38 (1.32–4.35) 0.0004
Age (change in 10 y) 1.14 (0.94–1.39) 0.17
Prefracture functional status
Using ambulatory aid versus independent
ambulator
1.54 (0.96–2.46) 0.07
Diabetes
Yes versus no 1.00 (0.60–1.64) 0.99
Level of the fracture line
Midcervical versus subcapital 0.83 (0.54–1.26) 0.37
Basal versus subcapital 0.85 (0.34–2.16) 0.73
Type of reduction
None versus open 1.3 (0.4–4.21) 0.66
Closed versus open 1.71 (0.52–5.59) 0.38
Time from injury to surgery (d) 0.99 (0.93–1.06) 0.76
Interaction 0.07
Smoking status
Current versus other (nonsmokers/
previous smokers) for cancellous
screws
1.39 (0.72–2.69) 0.33
Current versus other for sliding hip
screw
0.58 (0.28–1.21) 0.14
Treatment
Sliding hip screw versus cancellous
screws for current smokers
0.52 (0.22–1.24) 0.14
Sliding hip screw versus cancellous
screws for other (nonsmokers/previous
smokers)
1.25 (0.86–1.83) 0.25
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Pauwels fracture. This may have been due to a smaller
proportion of patients with fractures classiﬁed as type I (n =
93) or type III (n = 107) compared to type II (n = 615).
Although some evidence suggests that Pauwels classiﬁcation
may not be highly reliable, it is still widely used to classify
femoral neck fractures.16
The Gregersen et al9 trial found that underweight
elderly individuals (BMI ,19) had a lower risk of revision
surgery compared to elderly individuals with a BMI $ 19
(HR 0.33, 95% CI 0.11–0.95; P = 0.040). This ﬁnding was
similar to ours and may result from the increased amount of
stress on the implant.
Additionally, the Gregersen et al9 trial found that a high-
er risk of revision surgery was associated with living at home
independently compared to living in a nursing home (HR
2.67; 95% CI 1.35–5.31; P = 0.005) and with poor quality
of fracture reduction in displaced fractures (HR 1.95; 95% CI:
1.02–3.72; P = 0.040). Gregersen et al deﬁned poor reduction
as fracture displacement greater than 5 mm, an anteroposte-
rior Garden angle outside the interval of 160–175 degrees, or
a posterior or anterior angulation greater than 20 degrees.9,17
This ﬁnding was consistent with an earlier study which found
that poor reduction led to a higher risk of treatment failure
following internal ﬁxation of displaced fractures of the fem-
oral neck.18 Due to a low number of participants with an
unacceptable reduction, we did not include this factor in our
models. Review of the quality of fracture reduction by a Cen-
tral Adjudication Committee in the FAITH trial found that
only 5 participants had unacceptable reduction. Radiographs
of the hip fracture were examined by the Central Adjudication
Committee for approximation of the displaced fracture frag-
ments and overall fracture alignment. The Adjudication Com-
mittee assessed the quality of reduction. Although there are
radiologic predictors of failure, the absolute cutoffs for
acceptable and unacceptable reductions are not known.
Therefore, the Central Adjudication Committee erred on the
side of acceptable, except in cases where there was gross
malreduction, which rarely occurred.
To ensure that all conversion surgeries were captured,
our implant exchange model included conversion to THA,
HA, or another internal ﬁxation device.19 Arthroplasty in-
volves partial or full replacement of a joint, whereas internal
ﬁxation involves joint preservation. Therefore, the two pro-
cedures are very different clinically. For this reason, we
repeated the implant exchange analysis removing the 9 pa-
tients who underwent implant exchange to another internal
ﬁxation device. Typically, implant exchanges mostly involve
THA and HA procedures, whereas implant exchanges to
another internal ﬁxation device are less common. We found
similar results to our original analysis where female sex (P =
0.001), displaced fracture (P = 0.0003), and unacceptable
quality of implant placement (P = 0.006) were associated with
an increased risk of CS or SHS conversion to THA or HA.
Unlike in the original analysis, using an ambulatory aid pre-
fracture (P = 0.04) was also found to be associated with an
increased risk of CS or SHS conversion to THA or HA.
Our study has numerous notable strengths. A total of
1079 patients from 81 clinical sites in the United States,
Canada, Australia, the Netherlands, Norway, Germany, the
United Kingdom, and India were included in the FAITH trial.
The large sample size and diversity of the participants
included in the trial increases the external validity and
generalizability of our research ﬁndings from this analysis.
The 7 postsurgery follow-up visits across a 24-month period
allowed for frequent and long-term assessment of participant
outcomes and all revision surgery events were centrally
adjudicated. Additionally, the use of a multivariable Cox
proportional hazards regression for our analysis was advan-
tageous, as this type of model helps control for numerous
potentially confounding variables when the sample size is
large enough.20 Although this study had several strengths,
important limitations do exist. Although 1079 patients were
included in the primary analysis of the FAITH trial, it was not
possible to include them all in this analysis, due to missing
data. Also, it may be possible that not all factors associated
with revision surgery were collected as part of the FAITH
trial. Bone density determination is one important factor in
this regard. Only variables collected as part of the FAITH trial
could be used in our analysis.
Identifying factors associated with revision surgery will
help to optimize the care of hip fracture patients. Under-
standing which patients are at risk for revision surgery, and
speciﬁcally which type of revision surgery, can let surgeons
communicate these risks to patients when explaining treat-
ment options and prognosis. Additionally, the variables
identiﬁed in our analysis may allow for surgeons to consider
alternate care options, such as joint replacement, for patients
who are at higher risk of revision surgery. Finally, the results
of this study may also inform future research by identifying
high-risk patients who may beneﬁt from novel interventions
and adjuncts to care.
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